Literature DB >> 11122853

Recent developments in Barrett's esophagus.

H S Garewal1.   

Abstract

Barrett's esophagus is a precancerous condition in which the squamous esophageal epithelium is replaced by a columnar epithelium. Although different types of columnar epithelium have been described, the most frequently encountered is specialized columnar epithelium or intestinal metaplasia. Most investigators believe that increased cancer risk is only associated with this type. Esophageal adenocarcinoma is increasing in frequency in the United States and in Western Europe. Recent studies highlight the importance of gastroesophageal reflux disease in esophageal adenocarcinoma. Bile-acid reflux may also play a role. Increasing interest has been expressed in short-segment (2-3 cm) Barrett's esophagus. The contribution of short-segment Barrett's esophagus to cancer at the gastroesophageal junction is currently being studied. Although regular surveillance is often recommended, the commonness of Barrett's esophagus makes such a practice impractical for every patient. Biomarker development is needed to identify patients at greatest risk, with p53 a promising candidate based on recent studies. Initial data suggest that redox mechanisms may be involved in Barrett's esophagus. Several methods have recently been described for reversing Barrett's esophagus to squamous epithelium, but the significance of this practice in terms of reducing cancer risk remains to be demonstrated.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11122853     DOI: 10.1007/s11912-000-0078-9

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  41 in total

1.  Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota.

Authors:  G R Locke; N J Talley; S L Fett; A R Zinsmeister; L J Melton
Journal:  Gastroenterology       Date:  1997-05       Impact factor: 22.682

2.  High grade dysplasia/esophageal adenocarcinoma in short segment Barrett's esophagus.

Authors:  M Iqbal; G A Youngberg; M F Young; E Thomas
Journal:  South Med J       Date:  1997-08       Impact factor: 0.954

3.  Dynamic effects of acid on Barrett's esophagus. An ex vivo proliferation and differentiation model.

Authors:  R C Fitzgerald; M B Omary; G Triadafilopoulos
Journal:  J Clin Invest       Date:  1996-11-01       Impact factor: 14.808

4.  Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer.

Authors:  D C Farrow; T L Vaughan; P D Hansten; J L Stanford; H A Risch; M D Gammon; W H Chow; R Dubrow; H Ahsan; S T Mayne; J B Schoenberg; A B West; H Rotterdam; J F Fraumeni; W J Blot
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1998-02       Impact factor: 4.254

5.  Barrett's esophagus and the presence of Helicobacter pylori.

Authors:  R D Henihan; R C Stuart; N Nolan; T F Gorey; T P Hennessy; C A O'Morain
Journal:  Am J Gastroenterol       Date:  1998-04       Impact factor: 10.864

6.  Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia.

Authors:  W H Chow; W J Blot; T L Vaughan; H A Risch; M D Gammon; J L Stanford; R Dubrow; J B Schoenberg; S T Mayne; D C Farrow; H Ahsan; A B West; H Rotterdam; S Niwa; J F Fraumeni
Journal:  J Natl Cancer Inst       Date:  1998-01-21       Impact factor: 13.506

7.  Identification of intestinal-type Barrett's metaplasia by using the intestine-specific protein villin and esophageal brush cytology.

Authors:  A J MacLennan; M B Orringer; D G Beer
Journal:  Mol Carcinog       Date:  1999-02       Impact factor: 4.784

8.  Altered cadherin and catenin complexes in the Barrett's esophagus-dysplasia-adenocarcinoma sequence: correlation with disease progression and dedifferentiation.

Authors:  T Bailey; L Biddlestone; N Shepherd; H Barr; P Warner; J Jankowski
Journal:  Am J Pathol       Date:  1998-01       Impact factor: 4.307

9.  Barrett's esophagus. A prevalent, occult complication of gastroesophageal reflux disease.

Authors:  C Winters; T J Spurling; S J Chobanian; D J Curtis; R L Esposito; J F Hacker; D A Johnson; D F Cruess; J D Cotelingam; M S Gurney
Journal:  Gastroenterology       Date:  1987-01       Impact factor: 22.682

10.  Expression of beta-catenin, alpha-catenin, and E-cadherin in Barrett's esophagus and esophageal adenocarcinomas.

Authors:  K Washington; A Chiappori; K Hamilton; Y Shyr; C Blanke; D Johnson; J Sawyers; D Beauchamp
Journal:  Mod Pathol       Date:  1998-09       Impact factor: 7.842

View more
  2 in total

1.  Expression of bile acid transporting proteins in Barrett's esophagus and esophageal adenocarcinoma.

Authors:  Katerina Dvorak; George S Watts; Lois Ramsey; Hana Holubec; Claire M Payne; Carol Bernstein; Gareth J Jenkins; Richard E Sampliner; Anil Prasad; Harinder S Garewal; Harris Bernstein
Journal:  Am J Gastroenterol       Date:  2009-01-27       Impact factor: 10.864

2.  Transcriptional regulation of human mucin MUC4 by bile acids in oesophageal cancer cells is promoter-dependent and involves activation of the phosphatidylinositol 3-kinase signalling pathway.

Authors:  Christophe Mariette; Michaël Perrais; Emmanuelle Leteurtre; Nicolas Jonckheere; Brigitte Hémon; Pascal Pigny; Surinder Batra; Jean-Pierre Aubert; Jean-Pierre Triboulet; Isabelle Van Seuningen
Journal:  Biochem J       Date:  2004-02-01       Impact factor: 3.857

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.